89 annotations
stronger sales and marketing growth as we get to new launches in the second part of the year and the R&D continue to scale the growth
(No comment added)
Transcript
2024 Q2
9 Aug 24
We haven't yet lend in to all of our promotional channels and incretins.
You don't see, for instance, TV commercials in the incretins.
(No comment added)
Transcript
2024 Q2
9 Aug 24
For the first half, margins are a little inflated.
(No comment added)
Transcript
2024 Q2
9 Aug 24
Exceptional revenue growth in Q2 was driven by Mounjaro, Zepbound and Verzenio.
(No comment added)
Transcript
2024 Q2
9 Aug 24
tirzepatide demonstrated that up to 51.5% of participants met the criteria for disease resolution of sleep apnea
(No comment added)
Transcript
2024 Q2
9 Aug 24
FDA approval of Kisunla for treatment of Alzheimer's disease
(No comment added)
Transcript
2024 Q2
9 Aug 24
Mounjaro sales in Q2 were $3.1 billion globally with $2.4 billion in the U.S.
(No comment added)
Transcript
2024 Q2
9 Aug 24
Mounjaro was recently approved in China for type 2 diabetes and chronic weight management.
We have not yet announced expected launch timing in this market.
(No comment added)
Transcript
2024 Q2
9 Aug 24
further expand access to Zepbound with the launch of the 2.5-milligram and 5-milligram single-dose files in the coming weeks
(No comment added)
Transcript
2024 Q2
9 Aug 24
we expect increase in demand may result in periodic supply tightness for certain presentations and dose levels
(No comment added)
Transcript
2024 Q2
9 Aug 24
We are pleased that the group's supply situation is reflected on the FDA shortage website, which currently shows all doses of Mounjaro and Zepbound, listed as available and the two lower doses of Trulicity as available.
(No comment added)
Transcript
2024 Q2
9 Aug 24
unprecedented demand for our incretin medicines led to wholesaler back orders at the end of Q1
(No comment added)
Transcript
2024 Q2
9 Aug 24
it's barrier, but certainly is work to do is scaling manufacturing
(No comment added)
Transcript
2024 Q2
9 Aug 24
we had our Phase I MAD data for tirzepatide in 2016
(No comment added)
Transcript
2024 Q2
9 Aug 24
ambitious manufacturing expansion agenda
(No comment added)
Transcript
2024 Q2
9 Aug 24
this expansion will enhance -- to manufacture active pharmaceutical ingredients for Zepbound and Mounjaro
(No comment added)
Transcript
2024 Q2
9 Aug 24
weekly prescription volume was volatile in the first half of the year due to challenges fulfilling high demand, our progress on supply gives us confidence in our outlook
(No comment added)
Transcript
2024 Q2
9 Aug 24
non-incretin growth was 17% worldwide with growth spread across geographies
(No comment added)
Transcript
2024 Q2
9 Aug 24
Our primary strategy is self-run sites.
(No comment added)
Transcript
2024 Q2
9 Aug 24
we do rely on one of the Catalent sites for GLP-1 and other diabetes production
(No comment added)
Transcript
2024 Q2
9 Aug 24